Study of Paraesophageal Hernia Repair With Small Intestine Submucosa (PEH)
Recruitment status was: Active, not recruiting
In 2006 this research group reported their initial findings of a multi-center prospective trial comparing primary repair and primary repair buttressed with a biologic mesh made from porcine small intestinal submucosa (SIS). We were able to accrue 108 patients from 7/2002-3/2005 and followed each patient over 6 months and performed an UGI to check the durability of the repair and rule out a recurrence. The results suggested a significant benefit for the use of SIS mesh in the short-term, with the primary group having a 26% recurrence rate and the mesh group a 9% recurrence rate.
While these results are encouraging, it is important to know what is the durability and the longer term benefits of the use of SIS mesh. For this reason we propose a follow-up of the original study patients with the same outcome measures (symptom questionnaire, SF-36, and UGI). This should give us a very good idea about the long-term success of laparoscopic PEH repair with primary and SIS mesh.
|Hiatal Hernia Paraesophageal Hernia|
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Randomized Prospective Controlled Trial of Paraesophageal Hernia Repair With Small Intestine Submucosa (SIS)|
- To determine the medium/long-term effect of SIS on recurrence rates after laparoscopic PEH repair. [ Time Frame: One year ]
- Determine the objective durability of laparoscopic PEH repair with and without SIS [ Time Frame: One year ]
- Determine medium/long-term symptomatic outcomes of laparoscopic PEH repair with and without SIS [ Time Frame: One year ]
- Determine medium/long-term QOL outcomes of laparoscopic PEH repair with and without SIS [ Time Frame: One year ]
- Determine the incidence of long-term complications of SIS mesh for PEH repair (i.e. dysphagia, erosion, infection) [ Time Frame: One year ]
- Determine the durability of laparoscopic paraesophageal hernia repair with regard to a) anatomic recurrence b) symptom control [ Time Frame: One year ]
Biospecimen Retention: None Retained
|Study Start Date:||September 2008|
|Estimated Study Completion Date:||December 2009|
|Estimated Primary Completion Date:||July 2009 (Final data collection date for primary outcome measure)|
Phase I patients who had a paraesophageal hernia repair with synthetic mesh.
Phase I patients who had a paraesophageal hernia repair with small intestine submucosa mesh.
Traditionally paraesophageal hernias were repaired by thoracotomy or laparotomy with morbidity around 20% and mortality of 2%.1,2 The advent and later popularization of antireflux operations via the minimally invasive approach led to the development of a similar (laparoscopic) approach to the treatment of paraesophageal hernia. This approach called for the excision of the sac, a thorough esophageal mobilization, primary closure of the hiatus and a Nissen fundoplication. 3,4 Laparoscopy appears to have some of the benefits of thoracotomy (the hiatus can be accessed easier, the esophagus can be dissected under direct vision and high mobilization of the esophagus is possible) and some of the advantages of the laparotomy (less morbidity, no need to collapse the lung, no need for postoperative chest tube). In fact, most PEH are currently repaired via a laparoscopic approach.
Hashemi et al in 2000 reported that patients who had had a repair of a paraesophageal hernia via the laparoscopic approach had a higher recurrence rate when compared to those operated on via thoracotomy and laparotomy.5 The only other study comparing open and laparoscopic repair revealed a higher incidence of recurrence in the open repair group (8% vs. 0%),6 but was also based solely on symptoms. Case series of LPEHR which evaluate recurrent hiatal hernia by x-ray or endoscopy have found the recurrence rate to be between 12-42%,3,5,7 suggesting significant room for improvement.
It is not surprising that primary repair of the paraesophageal hiatal hernia by suturing the pillars of the diaphragm together under tension is at significant risk for disruption. With the development and wide application of mesh materials for tension-free repair of inguinal and ventral hernias, many surgeons have applied the technique of tension-free closure with a mesh to the hiatal hernia. Two randomized trials have demonstrated a significant reduction in recurrence rates by using synthetic mesh in large hiatal hernia repairs.8,9 However, there are potential problems introduced by using synthetic mesh at the dynamic hiatus such as mesh erosion, ulceration, stricture, and dysphagia.9,10,11 Recently, a number of biomaterials have been developed for hernia repair. The idea behind them is that a biologic scaffold, usually containing extracellular collagen, serves as a temporary matrix, thus strengthening a natural hernia closure.12,13 One such mesh is derived from porcine small intestinal submucosa (SIS) (Cook Surgical Indianapolis, IN). A pilot study using SIS for PEH repair suggested that is was safe and possibly effective in reducing recurrence.14 We then organized and carried out a multi-center randomized trial comparing primary repair of the crura and buttressing a primary repair with SIS mesh during laparoscopic PEH repair. The results at 6 months after operation demonstrated a nearly 3-fold reduction in the recurrence rate with the use of mesh (26% to 9%).15 Furthermore, there were no mesh related complications such as dysphagia, infection, or erosion. These results have been met with tempered enthusiasm in the surgical community. The only question in many surgeon's minds is whether buttressed repair of the hiatus is durable. To answer this question we need to complete longer term follow-up in these patients.
The aim of this study is to determine if the use of SIS to reinforce the closure of the hiatus in patients with paraesophageal hernias results in a lower recurrence rate at 2.5-5 years after operation, and results in improved outcomes, without an increase in the complication rate.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00786084
|United States, Missouri|
|Washington University School of Medicine|
|St Louis, Missouri, United States, 63110|
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 92701-3098|
|The Oregon Clinic, PC|
|Portland, Oregon, United States, 97227-1655|
|United States, Washington|
|University of Washington|
|Seattle, Washington, United States, 98105|
|Principal Investigator:||Brant K Oelschlager, MD||University of Washington|